Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Assuming Eli Lilly follows a similar timeline to tirzepatide, the earliest possible FDA approval for retatrutide would likely occur in late 2027 or 2028, depending on Phase 3 trial results and regulatory review timelines
The common link is that GLP-1s activate receptors that then work on driving down metabolic risk factors through the following mechanisms: Enhancing glucose dependent insulin secretion Slowing gastric emptying and decreasing appetite Reducing postprandial glucagon and food intake UpToDate 2 : (1) ingestion of food results in (2) release of gastrointestinal peptides (GLP-1 and GIP: glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide) and (3) pancreatic beta cell hormones (insulin and amylin)
Both drugs are GLP-1s, but Zepbounds active ingredient is tirzapetide and Wegovys is semaglutide
Spread protein across several smaller feedings rather than one or two large meals your appetite cannot finish
US$ 24.09
US$ 27.18
US$ 24.54
US$ 25.24
US$ 25.20
US$ 23.15
